48 gene Personalizing treatment solution in Lung Cancer
 

A comprehensive next generation sequencing approach identifies lung cancer-related genomic alterations. Detection of NCCN recommended genes and other lung cancer targeted and drug related genes, the assay provides biomarker information to guide personalized medication use for lung cancer patients.

 
Caner Type
Lung Caner
 
Biopsy Type
Tissue, FFPE, Peripheral Whole Blood
 
Results Expected
10 working days
Clinical significance
Indication of targeted drug efficiency

In addition to the routine recommendation to detect EGFR and ALK gene mutation, BRAF, MET, RET, ROS1, HER2 gene variants are also listed in the NATIONAL COMPREHENSIVE CANCER NETWORK as emerging target detection for non-small cell lung cancer. In 2017 PD-L1, ROS1 was incorporated into the NCCN guidelines and suggested a wider range of genetic testing.

 

1504329612310388.png

Noninvasive monitoring tumor progression, revealing drug resistance mechanisms, timely adjustment of treatment programs

After several splitting proliferation, the daughter of tumor cells showing a molecular biology or genetic changes, leading tumor growth rate, invasive ability, sensitivity to the drug, prognosis and etc., differences.  As a new tumor marker in the monitoring of the dynamic development of the tumor,ctDNA has a higher sensitivity and specificity, and can be better than the protein markers and imaging predict the dynamic development of the tumor. So ctDNA can be used for cancer early diagnosis, monitoring cancer development process, prognosis and individualized medication guidance.

 

1504329719395806.png

One patient carrying EGFR 19DEL and T790M mutation after osimertinib treatment, plasma ctDNA mutation disappeared and CT showed significant tumor shrinkage.

After 6 weeks of targeted treatment, ctDNA was almost difficult to detect, suggesting that the ctDNA can predict the therapeutic effect early first 6 weeks.
Product Content

 

Gene List (48)

0826肺癌48基因个体化治疗解决方案背面.jpg

 

Note:

NCCN recommended detection gene marked as red

Lung Cancer somatic mutation marked as white

MSI gene marked as blue

 

Targeted drugs
CFDA/FDA approved targeted drugs
  • Afatinib
  • Icotinib
  • Alectinib
  • Erlotinib
  • Gefitinib
  • Crizotinib
  • Nivolumab
  • Pembrolizumab
  • Ramucirumab
  • Nimotuzumab
  • Dabrafenib
  • Osimertinib
  • Ceritinib
Clinical test drugs
  • Abemaciclib
  • INC280
  • AZD4547
  • Onartuzumab
  • Binimetinib
  • Buparlisib
  • Dacomitinib
  • CO-1686
  • EGF816
  • Palbociclib
  • Dovitinib
  • Selumetinib
  • Patritumab
  • Rilotumulab
CFDA/FDA approved drugs for other cancer
  • Axitinib
  • Trametinib
  • Dasatinib
  • Vandetanib
  • Cabozantinib
  • Lapatinib
  • Vismodegib
  • Sunitinib
  • Cetuximab
  • Nintedanib
  • Trastuzumab
  • Panitumumab
  • Pertuzumab
  • Pazopanib
  • Regorafenib
  • Vemurafenib
  • Sorafenib
  • Temsirolimus

 


       

Service Process
  • Identify test program and fill in the application form

  • Get tissue and blood samples

  • Sign informed consent

  • Shipping to cloudhealth clinical center

  • Sequencing and analysis

  • Report

Reference

 

1.    Mok et al, 2009, N Engl J Med.

2.    llée A., et al. Lung Cancer; 2016, 91:73–74.

 


Immediate consultation or appointment testing services
Please select
  • 受检者
  • 研究人员
  • 医生
  • 公司
  • 其他

You can dial400-158-5999 The hotline contact us, or fill in your contact information and concerns, we will contact you in time